Boston Scientific’s Lotus transcatheter aortic valve replacement system demonstrated favorable outcomes in the REPRISE II trial and a 228-case series in the UK.
Earlier results from REPRISE II supported a CE mark for Lotus in 2013. Now the one-year follow-up data are...





